FMRP, USP, Brazil.
Braz J Otorhinolaryngol. 2010 Nov-Dec;76(6):713-7. doi: 10.1590/S1808-86942010000600008.
The efficacy of cidofovir in juvenile recurrent respiratory papillomatosis (JRRP) remains uncertain due to the lack of published case-control studies.
To establish factors affecting the progression of JRRP prognosis, and to evaluate cidofovir for eradicating JRRP.
Retrospective.
22 children with JRRP were evaluated at a referral center. All children underwent surgical debulking, followed by cidofovir injection (Group 2) or not (Group 1). Age at diagnosis was correlated with the Derkay score and disease outcome. Disease progression was compared between groups 1 and 2.
fifteen children were considered disease-free; 8 were in Group 2 and 7 in Group 1. Age and total and clinical scores (P<0.05) were negatively correlated. The mean number of surgeries required to control the disease was identical in both groups; the duration of treatment until remission was significantly higher in Group 1 (P<0,05).
JRRP is more aggressive in earlier onset disease. The duration of treatment was significantly lower in patients treated with cidofovir until eradication of JRRP compared to patients treated with surgery only.
由于缺乏已发表的病例对照研究，西多福韦治疗青少年复发性呼吸道乳头瘤病（JRRP）的疗效仍不确定。
确定影响 JRRP 预后进展的因素，并评估西多福韦根除 JRRP 的效果。
回顾性。
在一个转诊中心评估了 22 名患有 JRRP 的儿童。所有儿童均接受手术切除术，随后接受西多福韦注射（第 2 组）或不接受（第 1 组）。诊断时的年龄与 Derkay 评分和疾病结局相关。比较两组 1 和 2 之间的疾病进展情况。
15 名儿童被认为无疾病；8 名在第 2 组，7 名在第 1 组。年龄和总评分和临床评分（P<0.05）呈负相关。两组控制疾病所需的手术次数相同；第 1 组的治疗缓解持续时间明显更长（P<0.05）。
JRRP 在发病早期更为侵袭性。与仅接受手术治疗的患者相比，接受西多福韦治疗直至根除 JRRP 的患者的治疗持续时间明显更短。
